Capula Management LTD Gilead Sciences, Inc. Transaction History

Capula Management LTD

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	SELL	$76.01 - $86.7 $85,815 - $97,884	-1,129 Reduced 94.95%	60 $4,000
Q1 2023 May 10, 2023	SELL	$77.31 - $88.08 $1.02 Million - $1.17 Million	-13,251 Reduced 91.77%	1,189 $98,000
Q4 2022 Feb 14, 2023	BUY	$62.32 - $89.47 $256,072 - $367,632	4,109 Added 39.77%	14,440 $1.24 Million
Q3 2022 Nov 14, 2022	BUY	$59.54 - $68.01 $476,677 - $544,488	8,006 Added 344.34%	10,331 $637,000
Q2 2022 Aug 15, 2022	BUY	$57.72 - $65.01 $134,199 - $151,148	2,325 New	2,325 $144,000
Q4 2021 Feb 14, 2022	SELL	$64.88 - $73.64 $487,248 - $553,036	-7,510 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$67.69 - $73.03 $508,351 - $548,455	7,510 New	7,510 $525,000
Q2 2021 Aug 13, 2021	SELL	$63.47 - $69.35 $734,728 - $802,795	-11,576 Closed	0 $0
Q1 2021 May 14, 2021	SELL	$60.0 - $68.46 $4.37 Million - $4.98 Million	-72,794 Reduced 86.28%	11,576 $748,000
Q4 2020 Feb 16, 2021	SELL	$56.65 - $64.55 $2.36 Million - $2.69 Million	-41,691 Reduced 33.07%	84,370 $4.92 Million
Q3 2020 Nov 16, 2020	BUY	$62.1 - $78.08 $5.28 Million - $6.63 Million	84,971 Added 206.79%	126,061 $7.97 Million
Q2 2020 Aug 14, 2020	BUY	$72.34 - $84.0 $2.4 Million - $2.78 Million	33,129 Added 416.14%	41,090 $3.16 Million
Q1 2020 May 15, 2020	SELL	$62.63 - $80.22 $544,881 - $697,914	-8,700 Reduced 52.22%	7,961 $595,000
Q4 2019 Feb 14, 2020	SELL	$61.62 - $67.78 $7,887 - $8,675	-128 Reduced 0.76%	16,661 $1.08 Million
Q3 2019 Nov 14, 2019	BUY	$62.51 - $69.0 $1.05 Million - $1.16 Million	16,789 New	16,789 $1.06 Million

1,927

994M

10.5M

9.75M

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $114B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

Get notified when there are updates to the investment portfolio of Capula Management LTD, based on Form 13F filings with the SEC.

Stay updated on Capula Management LTD with notifications on news.